Moreau R, et al. - This randomized controlled trial assessed the impacts of long-term treatment with the fluoroquinolone norfloxacin on the survival of patients with cirrhosis. For this investigation, the researchers performed a double-blind trial of 291 subjects with Child-Pugh class C cirrhosis who had not received recent fluoroquinolone therapy. From April 2010 through November 2014, the study was performed at 18 clinical sites in France. Norfloxacin did not decrease 6-month mortality, estimated by the Kaplan-Meier method in a randomized controlled trial of patients with advanced cirrhosis without recent fluoroquinolone therapy. They observed that norfloxacin seems to increase survival of patients with low ascites fluid protein concentrations and significantly reduced the incidence of any and Gram-negative bacterial infections without increasing infections caused by Clostridium difficile or multiresistant bacteria.